A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1a,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1a,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract. 2015 Dec; 21(6):416-24.